Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study

Berning, Bernd; Kuijk, Cornelis van; Kuiper, Jan Willem; Bennink, Herjan J.T. Coelingh; Kicovic, P M; Fauser, Bart C.J.M.

doi:10.1016/s8756-3282(96)00219-0

Cited by 76 publications

(32 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estrogen deficiency in humans causes both trabecular bone loss and architectural deterioration, giving rise of an increased incidence of osteoporotic fracture 4,20,21 . Several studies have demonstrated that estrogen replacement therapy can effectively prevent trabecular as well as cortical bone loss by reducing bone resorption, showing to reduce the risk of skeletal fractures 4,20,22 . The present study confirms the estrogenic effect of tibolone at the femoral head reducing the bone resorption, since an increased bone density was found when compared to the OVX group.…”

Section: Cortical Bone Thicknessmentioning

confidence: 99%

“…No significant effect was found at skeletal sites dominated by cortical bone, including femoral neck, distal tibia and the diaphysis of both bones, being in accordance with previous observations 21,24 . Moreover, trabecular bone is much more responsive to hormonal as well as pharmacological intervention than cortical bone 22 . In our findings, only one ROIfemoral head in rats treated with tibolone -showed a significant increase in bone density, indicating less bone loss; no significant difference was found between the groups in the other locations analyzed.…”

Section: Cortical Bone Thicknessmentioning

confidence: 99%

See 1 more Smart Citation

Influence of estrogen deficiency and tibolone therapy on trabecular and cortical bone evaluated by computed radiography system in rats

Carvalho¹,

Fernandes²,

Lima

et al. 2012

Acta Cir. Bras.

View full text Add to dashboard Cite

PURPOSE: To verify the effects of tibolone administration on trabecular and cortical bone of ovariectomized female rats by computed radiography system (CRS). METHODS: The experiment was performed on two groups of rats previously ovariectomized, one received tibolone (OVX+T) while the other did not (OVX), those groups were compared to a control group (C) not ovariectomized. Tibolone administration (1mg/day) began thirty days after the ovariectomy and the treatment remained for five months. At last, the animals were euthanized and femurs and tibias collected. Computed radiographies of the bones were obtained and the digital images were used to determine the bone optical density and cortical thickness on every group. All results were statistically evaluated with significance set at P<0.05%. RESULTS: Tibolone administration was shown to be beneficial only in the densitometric analysis of the femoral head, performing higher optical density compared to OVX. No difference was found in cortical bone thickness. CONCLUSION: Ovariectomy caused bone loss in the analyzed regions and tibolone administered in high doses over a long period showed not to be fully beneficial, but preserved bone mass in the femoral head.

show abstract

Section: Cortical Bone Thicknessmentioning

confidence: 99%

Section: Cortical Bone Thicknessmentioning

confidence: 99%

Influence of estrogen deficiency and tibolone therapy on trabecular and cortical bone evaluated by computed radiography system in rats

Carvalho¹,

Fernandes²,

Lima

et al. 2012

Acta Cir. Bras.

View full text Add to dashboard Cite

show abstract

“…Apresenta propriedades estrogênicas, progestagênicas e androgênicas combinadas, através de seus metabólitos 3a-hidroxi, 3b-hidroxi e isômeros delta 4, respectivamente. Na dose de 2,5mg diários, têm demonstrado um efeito antireabsortivo, capaz de prevenir a perda óssea (30). Entretanto, ainda não existem estudos comprovando a diminuição da incidência de fraturas entre as usuárias de tibolona.…”

Section: Tibolonaunclassified

Terapêutica de reposição hormonal na osteoporose da pós menopausa

Pardini

1999

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOOs benefícios da terapia de reposição hormonal na prevenção e tratamento da osteoporose já são amplamente reconhecidos. Esta revisão tem por objetivo abordar os principais efeitos, mecanismos de ação e indicações dos principais esteróides utilizados na osteoporose da pós menopausa. Considerou erroneamente, na época, que a falta de estrógenos acarretava apenas uma diminuição da formação óssea. Atualmente, sabe-se que a perda óssea acelerada observada na pós menopausa é atribuída a um incremento do turnover ósseo, e tanto a formação como a reabsorção estariam aumentadas em decorrência da falência ovariana com predomínio da reabsorção, acarretando o aparecimento de fraturas osteoporóticas em cerca de 25% das mulheres em torno dos 75 anos (2). Garnero e cols. reportaram que nessa etapa da vida da mulher os marcadores de reabsorção aumentam em média 90%, enquanto que os de formação aumentam ao redor de 45% (3).A terapêutica de reposição hormonal (TRH) utilizada logo após a menopausa e durante 10 anos, reduz em 50% a incidência de fraturas osteoporóticas (4). Além do aspecto preventivo, já é consenso que ocorre aumento da massa óssea com o uso de TRH a longo prazo, mesmo em mulheres com osteoporose estabelecida, reduzindo em 50% o risco de fratura vertebral. ESTRÓGENOS Mecanismo de AçãoEmbora tenha decorrido mais de 50 anos desde a publicação de Albright, ainda é controverso o mecanismo exato de ação dos estrogênios no osso. Eles atuam a nível dos osteoblastos, onde foram identificados seus receptores (5), modulam a secreção endógena de calcitonina (6) e incrementam o número dos seus receptores ósseos (7). Os estrógenos também podem reduzir a perda óssea inibindo a síntese de prostaglandinas, principalmente as da série E, reduzem em cerca de 50% a produção do fator de necrose tumoral (TNF)

show abstract

“…With regard to bone metabolism, there are demonstrations of bone mineral density increase, reduction of bone turnover with reduction of the bone loss [8][9][10][11][12]. However, the majority of these studies evaluated relatively small populations and demonstration of reduction of fracture risk lacked, which made the substance has indication for prevention of bone loss and not for postmenopausal osteoporosis treatment [1].…”

mentioning

confidence: 99%

Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke

Melo

Pompei²

2009

Gynecological Endocrinology

View full text Add to dashboard Cite

Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study

Cited by 76 publications

References 24 publications

Influence of estrogen deficiency and tibolone therapy on trabecular and cortical bone evaluated by computed radiography system in rats

Influence of estrogen deficiency and tibolone therapy on trabecular and cortical bone evaluated by computed radiography system in rats

Terapêutica de reposição hormonal na osteoporose da pós menopausa

Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke

Contact Info

Product

Resources

About